James Song, MD

Utilizing Patient Factors to Guide Treatment Selection in Atopic Dermatitis

Video content above is prompted by the following:

What are some circumstances where you would prescribe an oral JAK inhibitor for moderate to severe AD initially over a biologic?

What advantages might a JAK inhibitor have over a biologic?

Videos

Experts discuss situations where an oral JAK inhibitor might be prescribed initially over a biologic for moderate to severe atopic dermatitis (AD), noting advantages such as oral administration, quicker onset of action, and convenience, which may make it a preferred option for some patients.

Oral JAK Inhibitors’ Place in Atopic Dermatitis Guidelines

What is the current place in therapy for JAK inhibitors in atopic dermatitis management, particularly when considering the spectrum of treatment options, including topical therapies and biologics?

Experts discuss the current place of JAK inhibitors in atopic dermatitis management, highlighting their role as an effective oral treatment option within the broader spectrum of therapies, including topical treatments and biologics, depending on disease severity and patient needs.

Effect of High-Impact Site Involvement on Quality of Life

What are some areas of the body that are particularly challenging to treat in psoriasis? What is your approach to treatment for these areas?

Panelists discuss how treating psoriasis in anatomically challenging areas such as the scalp, face, genitals, intertriginous zones, palms, soles, and nails requires specialized approaches due to unique barriers including limited penetration of topicals, skin sensitivity, mechanical friction, and psychological impact, necessitating tailored treatment strategies that may include modified vehicle formulations, careful steroid use, targeted phototherapy, or earlier consideration of systemic agents including biologics for these high-impact sites even when overall body surface involvement is limited.

Learnings From the VISIBLE Study in Skin of Color

Data, while limited, show that biologics are safe and effective treatment options across skin tones. How do you take these data into consideration when deciding on treatment for your patients with skin of color?

Panelists discuss how despite limited but encouraging efficacy and safety data from studies like VISIBLE (guselkumab) and various subgroup analyses supporting biologic use across diverse skin tones, clinicians must still consider unique presentations and concerns when treating patients with skin of color, including postinflammatory hyperpigmentation, follicular presentation patterns, cultural perspectives on treatment, and historical underrepresentation in clinical trials, while emphasizing the importance of personalized discussions about treatment expectations and outcomes specific to different skin phototypes.

James Song, MD

Articles